Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 238.

https://doi.org/10.1182/blood-2024-192995

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Sonia Godbole, Rina Li Welkie, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C. Reneau, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks, Yazeed Sawalha

Blood (2024) 144 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2024-207738

Published: 2024

Journal Articles

Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Y. Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2024) 144 (Supplement 1): 831.

https://doi.org/10.1182/blood-2024-209415

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Journal Articles

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Jia Ruan, David A. Bond, Bijal D Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Brittany Hobbie, Melinda Harbhajan, Tejasvi Sahni, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen-Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 746.

https://doi.org/10.1182/blood-2024-204495

Published: 2024

Journal Articles

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Blood (2024) 144 (Supplement 1): 6199.

https://doi.org/10.1182/blood-2024-204481

Published: 2024

Journal Articles

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2024-206559

Published: 2024

Journal Articles

Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

David A. Bond, Ying Huang, John C. Reneau, Yazeed Sawalha, Jonathan E. Brammer, Timothy Voorhees, Narendranath Epperla, Audrey M. Sigmund, Lapo Alinari, Walter Hanel, Anna Gilmore, Misty Fleming, Kathleen Stamper, Robert Baiocchi, Beth Christian, Kami J. Maddocks

Blood (2024) 144 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2024-194545

Published: 2024

Journal Articles

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Pranav Santapuram, Jason T Romancik, Jonathon B Cohen, Melissa Kives, Manali Rupji, Javier Pinilla-Ibarz, Kami J. Maddocks, Craig A. Portell, Joanna M. Rhodes, Brian K. Link

Blood (2024) 144 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2024-204002

Published: 2024

Journal Articles

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2024-203798

Published: 2024

Journal Articles

Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)

John Sharp, Subodh Bhatta, Noah Takacs, Kathleen Tong, Youssef Youssef, David A. Bond, Yazeed Sawalha, Audrey M. Sigmund, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Kami J. Maddocks, Beth Christian, Timothy Voorhees, Narendranath Epperla

Blood (2024) 144 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2024-194399

Published: 2024

Journal Articles

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Greg Kirkpatrick, Jeffrey M. Switchenko, Melissa Kives, Katelin Baird, Kami J. Maddocks, Jason T. Romancik, Deborah M. Stephens, Harsh Shah, Javier Pinilla-Ibarz, Julio C Chavez, Matthew Matasar, Craig A. Portell, Michelle Churchman, Jonathon B. Cohen, Umar Farooq, Brian K. Link

Blood (2023) 142 (Supplement 1): 6325.

https://doi.org/10.1182/blood-2023-187198

Published: 2023

Journal Articles

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Blood (2023) 142 (Supplement 1): 380.

https://doi.org/10.1182/blood-2023-189505

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Yazeed Sawalha, Rina Li Welkie, Anna Krivenko, Brian Hess, Audrey M. Sigmund, Timothy Voorhees, Walter Hanel, David A. Bond, John C Reneau, Narendranath Epperla, Lapo Alinari, Jonathan E. Brammer, Beth Christian, Robert Baiocchi, Kami J. Maddocks

Blood (2023) 142 (Supplement 1): 6226.

https://doi.org/10.1182/blood-2023-182941

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2023-180048

Published: 2023

Journal Articles

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Maurizio Di Liberto, Yang Hu, Xiangao Huang, Giorgio Inghirami, Kevin Wang, Christina Lee, Kami J. Maddocks, Kristie A. Blum, Jia Ruan, John P. Leonard, Nancy L. Bartlett, Peter Martin, Olivier Elemento, Selina Chen-Kiang

Blood (2023) 142 (Supplement 1): 50.

https://doi.org/10.1182/blood-2023-190308

Published: 2023

NARROW

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis

Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)

Overall Survival Following First and Second Relapse of DLBCL Treated with Therapies Including Autologous Transplant and CAR-T Cells: Results from the Lion Prospective Observational Registry

Ki-67 Expression of 50% Is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Harnessing Btki Therapy By CDK4/6i Control of T Effector Memory Cells and T Cell Surveillance in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only